DXCM - DexCom expects Q4 revenue to be up Y/Y
- Glucose monitoring company DexCom ( NASDAQ: DXCM ) expects Q4 revenue to be at least $815M, an increase of 17% Y/Y on a reported basis and 20% on an organic basis.
- The Q4 revenue consensus stands at $808M.
- U.S. segment's revenue is expected to be ~$606M, up 17% Y/Y.
- International segment's revenue is expected to be ~$209M, an increase of 15% Y/Y on a reported basis and 26% on an organic basis.
- FY22 revenue is expected to be ~$2.91B, an increase of 19% Y/Y on a reported and organic basis. Consensus is $2.9B.
- For FY23, Dexcom anticipates a revenue of ~$3.35B to $3.49B, representing expected growth of ~15% to 20% Y/Y. Consensus is $3.47B.
- The outlook considers sensor volume growth driven by increasing CGM awareness for people with diabetes, the launch of the Dexcom G7 CGM system in the U.S. and its continued rollout in international markets, further international expansion and overall market dynamics.
- FY23 non-GAAP gross profit margin is anticipated to be 62% to 63%, while non-GAAP operating margin of ~16.5%.
- The company will report its audited Q4 and FY22 financial results on Feb. 9 after market close.
- DXCM shares were trading ~5% down.
- Source: Press Release
For further details see:
DexCom expects Q4 revenue to be up Y/Y